Settlement guide
The company’s July 27, 2026 notice proposes terms for ovarian talc claims. It has conditions.
Updated Oct 4, 202618 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated Oct 4, 202618 sources
This may apply to you if
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
Freda L. Wolfson · United States District Court for the District of New Jersey · Retired district judge serving as a limited-purpose special master
Finding: The January 2026 report recommends how to resolve challenges to expert testimony in the ovarian talc cases. It does not award personal injury payments or state a final result for every claim.
District of New Jersey: January 20, 2026 talc expert-evidence report (opens in a new tab) · Jan 20, 2026 · Checked Oct 3, 2026
NIEHS, with collaborating US cohort investigators · JAMA · 2020
Read the source: 2020 pooled genital-powder and ovarian-cancer study (opens in a new tab) · Checked Oct 3, 2026
NIEHS, with collaborating cancer and epidemiology investigators · Journal of Clinical Oncology · 2024
Read the source: 2024 Sister Study quantitative bias analysis (opens in a new tab) · Checked Oct 3, 2026
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
The company’s July 27, 2026 notice proposes terms for ovarian talc claims. It has conditions. Its totals do not show your payment or prove that you are included.
The company proposed terms for ovarian talc claims on July 27, 2026. It has conditions. The notice does not confirm that all claims are settled.
It has a separate statement about past mesothelioma settlements. It warns that timing and outcomes may differ from expectations. Keep the company announcement distinct from an agreement for your claim and from a court’s final decision.
No one has announced a personal payout grid in the July 27 company notice reviewed here. Its totals do not tell you what you would receive.
A total promised for the future is not one person’s award, signed offer or take-home amount. Ask for the actual terms addressed to your claim instead of turning a company total into an online average.
Ask a lawyer to check the cancer, proof and terms. The proposal has a condition about who joins. It does not promise you money.
The company says the proposal needs participation representing at least 95% of remaining claims. Ovarian studies have differing findings and limits; neither supplies a damages table or proves that a particular powder caused your cancer.
Get the fee and expense terms in writing. A model fee rule is not this firm’s agreement. Ask whether contact costs money.
The ABA model rule addresses percentages, expense deductions and costs that could remain after a loss. Ask how the actual agreement treats expenses and which other deductions need a legal check.
The notice sets no pay date for each person. Ask what your own agreement requires and whether those conditions have been met.
The January 2026 court report is about expert-evidence recommendations. It is not a payment order. Neither a recommendation nor a company’s forward-looking schedule certifies that a particular claimant has been paid.
Ask what primary record supports the range and whom it covers. Do not treat a company total as an estimate for your case.
The 2020 ovarian study could miss a small increase. The later positive analysis uses bias assumptions and shares an earlier study group. Those clinical findings do not assign a claim value. Keep the actual medical and legal evidence separate from advertising.
Prepare your care reports, product history and any offer. Ask which law, deadline and written terms apply before relying on a proposed program.
Use the provider’s process for missing covered medical records, subject to exceptions. Tell the lawyer whether you already filed or signed an agreement. A company announcement does not substitute for an individual filing-limit review.
The review is free and private. Asking for it doesn’t commit you to anything.
Register your interestThere is no reliable average. No one has announced a personal payout amount: J&J's July 27, 2026 proposal for ovarian claims describes possible aggregate payments with conditions, including participation representing at least 95% of remaining claims, not what any one person would receive. Jury verdicts in individual cases have varied widely, and some were later reduced on appeal; they do not predict another case. What any claim is worth depends on its facts, and no one can promise an amount.
They are separate. Claims against talc supplier Imerys Talc America go through its bankruptcy process, which sets its own claim rules. Claims against J&J proceed in MDL 2738 or in state courts, and J&J's July 27, 2026 proposal for ovarian claims has its own conditions. A lawyer can tell you which, if either, applies to you. J&J's announcement does not say what any one person would receive. What any claim is worth depends on its facts, and no one can promise an amount.
No one can say whether an individual case will go to trial. The MDL process is specifically designed to resolve thousands of cases efficiently. In many MDLs, test (bellwether) trials help the parties assess cases, but their results do not set what another claim is worth. On July 27, 2026, J&J announced a proposed resolution of ovarian claims that depends on participation representing at least 95% of remaining claims. Some plaintiffs in state court may reach trial faster than the MDL timeline. Your attorney handles all filings and communications, and you do not need to attend court proceedings in most cases.
Checked against 16 primary sources by People's Justice editors · Updated
How we make moneyPeople's Justice research team · Updated Oct 4, 2026